Article
Overexpression of ERCC6L correlates with poor prognosis and confers malignant phenotypes of lung adenocarcinoma.
Oncology reports - 1 Jul 2022
Huang Xiaoyue, Jiang Lingyu, Lu Sufang, Yuan Mingqing, Lin Hui, Li Baijun, Wen Zhaoke, Zhong Yonglong
Abstract excerpt
Excision repair cross‑complementation group 6 like (ERCC6L) has been reported to be upregulated in a variety of malignant tumors and plays a critical oncogenic role. However, the role and molecular mechanism of ERCC6L in lung adenocarcinoma (LUAD) remain unclear, and were therefore investigated in the present study. Clinical data of patients with LUAD were obtained and bioinformatics analysis was performed to...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
